(NASDAQ: REGN) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the resubmission of the Biologics License Application (BLA) for linvoseltamab for the treatment ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback